View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 7, 2017updated 22 Nov 2021 12:39pm

Deals this week: Mundipharma Medical Company, Cooper Pharmal Sarl, Merck

Mundipharma Medical Company will exclusively distribute INVOKANA (canagliflozin) and VOKANAMET (canagliflozin and metformin) in the European Economic Area (EEA) and Switzerland, under an agreement signed with drug developer and manufacturer Janssen Pharmaceutica NV.

Mundipharma Medical Company will exclusively distribute INVOKANA (canagliflozin) and VOKANAMET (canagliflozin and metformin) in the European Economic Area (EEA) and Switzerland, under an agreement signed with drug developer and manufacturer Janssen Pharmaceutica NV.

Janssen is a Johnson & Johnson subsidiary based in Belgium.

Mundipharma Medical has exclusive rights to promote, distribute and sell the two products through its network of independent associated companies within the concerned countries.

Moroccan pharmaceutical company Cooper Pharmal Sarl has signed an agreement with BioQ Pharma to commercialise the latter’s Ropivacaine ReadyfusOR post-surgical pain management therapy in Morocco.

The drug is a disposable, ready-to-use, single use infusion product used for managing post-surgical pain in adults.

Merck has announced its intention to sell its consumer health business either fully or partially.

“Moroccan pharmaceutical company Cooper Pharmal Sarl has signed an agreement with BioQ Pharma to commercialise the latter’s Ropivacaine ReadyfusOR post-surgical pain management therapy in Morocco.”

The German science and technology company is also evaluating the option to form strategic partnerships instead of a sale.

US-based biopharmaceutical company Insmed intends to raise up to $250m through the public offering of shares of its common stock.

Underwriters to the offer are granted a 30-day option to buy up to an additional 15% of the shares on offer at the public offering price.

Rhythm Pharmaceuticals has filed a registration statement for its initial public offering (IPO) of shares of its common stock.

The company intends to raise up to $115m from the IPO.

Underwriters to the offering are granted a 30-day option to purchase additional shares.

Based in the US, Rhythm Pharmaceuticals is a peptide therapeutics developer.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology